6:30 PM - 7:00 PM Dinner and Registration
7:00 PM - 7:10 PM Welcome and Introduction
7:10 PM - 7:20 PM History and Development of Immunotherapy in Bladder Cancer
7:20 PM - 8:50 PM Case Discussions
- Neoadjuvant and adjuvant immunotherapy approaches
- Optimal use of immune checkpoint inhibitors for first-line therapy in advanced disease
- Immune checkpoint inhibitors after progression on platinum-based chemotherapy
- Administration considerations and immune-related adverse event management
- Options for treatment after discontinuing immune checkpoint inhibitors
Faculty Panel Discussion and Audience Questions
For each case presented, faculty will lead a discussion on available clinical data that could guide the treatment choice for the case.
8:50 PM - 9:00 PM Final Thoughts and Audience Question and Answer Session
Date / Time
San Francisco, California
San Francisco Marriott Marquis
Elizabeth Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Andrea Apolo, MD
Genitourinary Malignancies Branch
Head, Bladder Cancer Section
NIH Lasker Clinical Research Scholar
National Cancer Institute Center for Cancer Research
Jean Hoffman-Censits, MD
Department of Medical Oncology
Sidney Kimmel Cancer Center at Jefferson
Matthew Milowsky, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of North Carolina at Chapel Hill
North Carolina Cancer Hospital
Chapel Hill, North Carolina
The goal of this activity is to improve participants’ competence and performance in using immune checkpoint inhibitors to improve outcomes for patients with locally advanced or metastatic urothelial carcinoma.
This program is intended for physicians and other healthcare providers who care for patients with urothelial bladder cancer.
- Gain insight on the mechanism of action and rationale for using immune checkpoint inhibitors to treat patients with advanced urothelial carcinoma
- Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, considering the available evidence, patient and disease characteristics, as well as patient preferences
- Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors
- Evaluate the benefits of monotherapy and combination checkpoint inhibitor therapies as part of first-line, second-line, and subsequent lines of therapy for advanced urothelial carcinoma
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, Clinical Care Options, LLC and the Bladder Cancer Advocacy Network. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.